Skip to main content

Table 4 Drug interactions with gemfibrozil

From: Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders

Concomitant medication

Cautions

HMG-CoA Reductase Inhibitors

risk of myopathy and rhabdomyolysis

Anticoagulants

warfarin dosage should be reduced

CYP2C8 Substrates

drugs metabolized CYP2C8 (e.g., dabrafenib, loperamide, montelukast, paclitaxel, pioglitazone, rosiglitazone) may be required to reduce

OATP1B1 substrates

substrates of OATP1B1 (e.g., atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan) may be required to reduce

Bile Acid-Binding Resins

resin-granule drugs such as colestipol (5 g) are recommended at 2 or more hours apart

Colchicine

myopathy, including rhabdomyolysis in chronic administration of colchicine

  1. SPC of LOPID issued March.2016